Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001641172-25-011502
Filing Date
2025-05-19
Accepted
2025-05-19 16:59:33
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A formdefa14a.htm DEFA14A 1907580
2 GRAPHIC ex99-1_001.jpg GRAPHIC 22258
3 GRAPHIC ex99-1_002.jpg GRAPHIC 10886
  Complete submission text file 0001641172-25-011502.txt   1954821
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-12555 | Film No.: 25964857
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)